
Novartis' Iptacopan Phase III study, APPEAR-C3G, reveals a significant reduction in proteinuria in patients with C3 glomerulopathy (C3G). The trial met its primary endpoint, showcasing iptacopan's superiority over placebo in reducing proteinuria alongside standard therapy. C3G is an ultra-rare complement-mediated kidney disease with no current targeted treatments. Novartis aims to discuss results with health authorities for potential 2024 submissions. Iptacopan, a Factor B inhibitor, has shown promise in IgA nephropathy and recently gained FDA approval for paroxysmal nocturnal hemoglobinuria
Like
Save
Share